Sinotau Pharmaceutical Group
Clinical trials sponsored by Sinotau Pharmaceutical Group, explained in plain language.
-
Radioactive injection shows promise in slowing neuroendocrine tumor growth
Disease control OngoingThis Phase 3 study tested a radioactive drug called Lutetium-177 oxodotreotide against a high dose of the standard drug octreotide in 196 people with advanced neuroendocrine tumors that had stopped responding to treatment. The main goal was to see if the radioactive drug could de…
Phase: PHASE3 • Sponsor: Sinotau Pharmaceutical Group • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
Radioactive injection targets Hard-to-Treat tumors in new trial
Disease control OngoingThis study tests a radioactive drug called Lutetium-177 oxodotreotide in 74 people with advanced neuroendocrine tumors that have spread and are growing despite other treatments. The drug is designed to seek out and deliver radiation directly to tumor cells. Researchers are checki…
Phase: PHASE2, PHASE3 • Sponsor: Sinotau Pharmaceutical Group • Aim: Disease control
Last updated Jun 26, 2026 13:58 UTC